作者
Yinghong Wang, Diana H Wiesnoski, Beth A Helmink, Vancheswaran Gopalakrishnan, Kati Choi, Hebert L DuPont, Zhi-Dong Jiang, Hamzah Abu-Sbeih, Christopher A Sanchez, Chia-Chi Chang, Edwin R Parra, Alejandro Francisco-Cruz, Gottumukkala S Raju, John R Stroehlein, Matthew T Campbell, Jianjun Gao, Sumit K Subudhi, Dipen M Maru, Jorge M Blando, Alexander J Lazar, James P Allison, Padmanee Sharma, Michael T Tetzlaff, Jennifer A Wargo, Robert R Jenq
发表日期
2019/1
期刊
Nature medicine
卷号
25
期号
1
页码范围
188-188
出版商
Nature Publishing Group US
简介
Results:
Published text:“Four of the five monoclonal antibodies (CIS23, CIS34, CIS42 and CIS43) showed dose-dependent binding to rPfCSP and PfSPZ in an ELISA and had maximal effective concentrations (EC50s) ranging 0.003–0.134 μ g/ml and 0.017–0.08 μ g/ml, respectively (Fig. 1c).” Correct text:“Four of the five monoclonal antibodies (CIS23, CIS04, CIS42 and CIS43) showed dose-dependent binding to rPfCSP and PfSPZ in an ELISA and had maximal effective concentrations (EC50s) ranging 0.003–0.134 μ g/ml and 0.017–0.08 μ g/ml, respectively (Fig. 1c).”
学术搜索中的文章
Y Wang, DH Wiesnoski, BA Helmink, V Gopalakrishnan… - Nature medicine, 2019